DXCM: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-10-16
⚠ AI Risk Brief Interpretation layer — deterministic data below

Share buyback uncertainty and pricing pressure create elevated financial risk alongside regulatory compliance challenges from FDA warning letter.

Direction ↑ More concerning
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
0
Removed
5
Modified
69
Unchanged
🟢 New in Current Filing Disclosure change7/10

We cannot guarantee that the 2025 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.

🟡 Modified If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows. 🔒
🟡 Modified If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market. 🔒
🟡 Modified Climate change may have an adverse impact on our business. 🔒

And 2 more changes in the full comparison.

5 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get Pro access Already a Pro subscriber? View full diff →